Novo Nordisk CEO on earnings: Very bullish on 2025 despite demand concerns
0
0
07/11/24
Dans
Amérique du Nord / États-Unis
Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Money Movers' to discuss Jorgensen's comments on demand in 2025, if demand is waning for GLP-1 drugs, and much more.
Montre plus
0 commentaires
sort Trier par
